Ketek is a drug owned by Sanofi Aventis Us Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 01, 2018. Details of Ketek's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5635485 | Erythromycin compounds |
Apr, 2018
(6 years ago) |
Expired
|
| USD459798 | Pill tablet |
Sep, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Ketek is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ketek's family patents as well as insights into ongoing legal events on those patents.
Ketek's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ketek's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 01, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ketek Generics:
There are no approved generic versions for Ketek as of now.
Alternative Brands for Ketek
Ketek which is used for treating respiratory infections caused by susceptible strains of designated microorganisms in adults over 18 years old., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Si Pharms |
| |||
About Ketek
Ketek is a drug owned by Sanofi Aventis Us Llc. It is used for treating respiratory infections caused by susceptible strains of designated microorganisms in adults over 18 years old. Ketek uses Telithromycin as an active ingredient. Ketek was launched by Sanofi Aventis Us in 2005.
Approval Date:
Ketek was approved by FDA for market use on 09 February, 2005.
Active Ingredient:
Ketek uses Telithromycin as the active ingredient. Check out other Drugs and Companies using Telithromycin ingredient
Treatment:
Ketek is used for treating respiratory infections caused by susceptible strains of designated microorganisms in adults over 18 years old.
Dosage:
Ketek is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 400MG | TABLET | Discontinued | ORAL |
| 300MG | TABLET | Discontinued | ORAL |